BG Medicine Announces Research Agreement With Boston Scientific

BG Medicine, Inc.

today announced that it has entered into a research collaboration agreement with Boston Scientific Corporation

to study the role of galectin-3 as an aid in patient screening for cardiac-resynchronization therapy (

) using patient data from the MADIT-CRT study. The collaboration is designed to focus on better understanding the important MADIT-CRT patient population and whether galectin-3 can help identify patients who would derive the most benefit from CRT. This collaboration also involves using BG Medicine's biomarker discovery capabilities to identify other biomarkers that correlate to CRT treatment response.